Navigation Links
Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Date:7/28/2009

PRINCETON, N.J., July 28 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced the appointment of Daniel E. Leone as Vice President of Business Development. Mr. Leone will be responsible for Laureate's worldwide business development activities, including sales and marketing. He will be supporting the company's contract development, manufacturing, and bioprocessing business.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased to welcome Dan to Laureate's Leadership Team," said Robert J. Broeze, Ph.D., President and CEO of Laureate. "Dan is a seasoned executive with more than 20 years of experience in business development and he brings an impressive background that includes broad international business development and management experience in contract manufacturing, pharmaceuticals and specialty chemicals. His capabilities include strong leadership, and strategic and organizational skills that have produced positive results in early stage and mature businesses."

Most recently Dan served as Executive Director of Contract Manufacturing at Ben Venue Laboratories where he was responsible for Sales, Marketing and New Business Development for its parenteral contract manufacturing services business. Prior to Ben Venue, Dan was the Vice President of Business Operations at Boehringer Ingelheim Chemicals where he was responsible for Sales, Marketing, New Business Development and Supply Chain Management for its active pharmaceutical ingredients business. Prior to BI, Dan held positions of increasing responsibility at Hoechst Corporation. While at Hoechst Dan served as their Global Director, Ventures in Hoechst
'/>"/>

SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
2. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
3. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. Laureate Announces Manufacturing Agreement with Tolerx
7. Laureate Pharma to Add More Manufacturing Capacity
8. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
9. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
10. Laureate Pharma Reports Record Growth for 2007
11. Laureate Pharma Appoints Gary Swan as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalyst™ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... 25, 2015 Optimal Research, LLC has been ... (ViE) Award "Best Clinical Site or Trial Network". ... has been selected as a nominee in this ViE ... "Highly Recommended" distinction in 2014. The ViE awards were ... accomplishments, and positive contributions of companies and individuals in ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... ... 2, 2009. , ... Portland, Maine (PRWEB) June 26, 2009 -- IntertechPira, in conjunction with the National Hydrogen ... conference bringing together hydrogen producers, developers and users to discuss the future of this ...
... , , , , NORCROSS, Ga., ... in providing automated instrument-reagent systems to the blood transfusion industry, ... an administrative action based on an early January 2009 inspection, ... license with respect to its Reagent Red Blood Cells and ...
... Clavis Pharma ASA (OSE:,CLAVIS) today announced that the Company ... gross proceeds through a private placement,of 10,750,000 new shares, each ... of NOK,12.00 per share (the "Private Placement"). , ... process and was,managed by Carnegie ASA and DnB NOR Markets ...
Cached Biology Technology:Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC 2Immucor Responds To FDA Notice 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 2Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 3Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 4Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 5
(Date:3/18/2015)... CORAL SPRINGS, Florida , March 18, 2015 ... as well as businesses, new revolutionary smart wallets and apps ... rapid pace.  Companies currently entrenched in the mobile payment industry ... ), Alibaba Group Holding Ltd. (NYSE: BABA ), ... GOOG ) and Facebook Inc. (NASDAQ: ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... 12, 2015 WHEN:Tuesday, March 17, 2015 at ... http://bit.ly/1G7Os0L . SPEAKERS: , Frost & Sullivan Measurement ... http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies must plan ... several different markets and industries. This is especially ... uptrend. Join Frost & Sullivan,s ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... developer and manufacturer of advanced molecular sensing and imaging ... that it has signed exclusive distribution deals for both ... markets covered include Australia, New Zealand, The Netherlands, ... Greece, Turkey, and Russia. The values of the ...
... for U.S. Department of Agriculture,s (USDA) Center for Veterinary Biologics ... each batch of a vaccine, the CVB has informed PETA ... with modern non-animal methods. The USDA has amended its Web ... CVB to follow the lead of Europe in adopting an ...
... newswire / - ERGONEX Pharma received one of the ... occasion of Frost & Sullivan,s ,2009 Excellence in Healthcare ... The highly competitive award was presented to ERGONEX Pharma ... impressive display of technological know-how and targeted vision. , ...
Cached Biology News:Spectros Signs New International Distribution Deals 2ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009 2
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
... White to off-white solid. A ... and blocks the formation of N-glycosidic ... against Gram-positive bacteria, yeasts, fungi, ... functional thrombin receptors on human T-lymphoblastoid ...
... enzymes involved in matrix degradation. Of the ... exist in soluble form whereas MT-MMPs exist ... also known as MMP14, MMP15, MMP16 respectively ... to the cell surface. They have an ...
...
Biology Products: